# TRUDI: TDXD+Durva in HER2+/Low IBC

> **NCT05795101** · PHASE2 · RECRUITING · sponsor: **Filipa Lynce, MD** · enrollment: 63 (estimated)

## Conditions studied

- Invasive Breast Cancer
- Inflammatory Breast Cancer Stage III
- HER2-positive Breast Cancer
- HER2 Low Breast Adenocarcinoma
- Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05795101
- **Lead sponsor:** Filipa Lynce, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-04
- **Primary completion:** 2027-12-01
- **Final completion:** 2032-12-01
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05795101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05795101, "TRUDI: TDXD+Durva in HER2+/Low IBC". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05795101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*